Post-earnings recap
Reported
Tue, Apr 28, 2020
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that CRISPR Therapeutics is facing challenges, particularly reflected in the negative EPS. The stock fell 4.51% following the announcement, likely due to the lack of revenue figures and guidance, which leaves investors uncertain about the company's near-term performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.15 | N/A | -5.50% |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious outlook for the future. They emphasized their commitment to ongoing clinical development but did not offer specific guidance.
Management did not provide specific revenue guidance for the upcoming quarters.
The company is focusing on advancing its clinical programs despite the current challenges.